Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioural the

1. Wadden T, Bailey TS, Billings LK, et al. Semaglutide 2.4 mg and Intensive Behavioral Therapy in Subjects with Overweight or Obesity (STEP 3). Presented at the 38th Annual Meeting of The Obesity Society (TOS) held at ObesityWeek, November 2-6, 2020 [Oral 084]. 2. J Blundell, G Finlayson, M Axelsen, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017; 19:1242-1251. 3. J Lau, P Bloch, L Schaffer, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015; 58:7370-80. 4. ClinicalTrials.gov. Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program (STEP 3). Available at: https://clinicaltrials.gov/ct2/show/NCT0... [https://clinicaltrials.gov/ct2/show/NCT0...]. Last accessed: November 2020. 5. Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020; 28:1050-1061. 6. American Medical Association. A.M.A Adopts New Policies on Second Day of Voting at Annual Meeting. Obesity as a Disease. Available at: http://news.cision.com/american-medical-association/r/ama-ad... cies-on-second-day-of-voting-at-annual-meeting,c9430649 [http://news.cision.com/american-medical-association/r/ama-ad... icies-on-second-day-of-voting-at-annual-meeting,c9430649]. Last accessed: November 2020. 7. WHO. Obesity: Preventing and managing the global epidemic. Available at: http://www.who.int/iris/handle/10665/423... [http://www.who.int/iris/handle/10665/423...] Last accessed: November 2020. 8. DP Guh, W Zhang, N Bansback, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009; 9:1-20. 9. A Peeters, JJ Barendregt, F Willekens, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Annals of Internal Medicine. 2003; 138:24-32. 10. AS Gami, SM Caples and VK Somers. Obesity and obstructive sleep apnea. Endocrinology and Metabolism Clinics of North America. 2003; 32:869-94. 11. G Vernon, A Baranova and ZM Younossi. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011; 34:274-85. 12. G Whitlock, S Lewington, P Sherliker, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009; 373:1083-96. 13. World Health Organization. Obesity and Overweight Factsheet no. 311. Available at: http://www.who.int/mediacentre/factsheet... [http://www.who.int/mediacentre/factsheet...]. Last accessed: November 2020.

[i] Included behavioural support and dietician counselling, reduced-calorie diet (with a structured low-calorie diet of 1,000-1,200 kcal/day for the first eight weeks followed by hypo-caloric diet), and increased physical activity of up to 200 minutes per week

CONTACT: Media: Mette Kruse Danielsen, +45 3079 3883, mkd@novonordisk.com.Ken Inchausti (US), +1 609 240 9429, kiau@novonordisk.com. Investors:Daniel Muusmann Bohsen, +45 3075 2175, dabo@novonordisk.com. Valdemar BorumSvarrer, +45 3079 0301, jvls@novonordisk.com. Ann Sndermlle Rendbk,+45 3075 2253, arnd@novonordisk.com. Mark Joseph Root, +45 3079 4211,mjhr@novonordisk.com. Kristoffer Due Berg (US), +1 609 235 2989,krdb@novonordisk.com.